Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions largely revolve around the comparative efficacy of ensartinib against crizotinib, with several posts citing specific statistics such as a median progression-free survival of 25.8 months for ensartinib versus 12.7 months for crizotinib. Phrases like 'clearly superior' and 'potential new first-line treatment option' illustrate a positive sentiment towards ensartinib, reflecting excitement and a promising outlook for patient care. The overall tone is optimistic, indicating a collective recognition of the study's groundbreaking nature in oncology.
Most discussions reflect strong support for the findings of the trial, highlighting ensartinib's superiority over crizotinib.
The discussions express a high level of curiosity and relevance regarding the advancements presented in the study.
Many posts delve into detailed statistics and outcomes from the trial, showing deep engagement with the content.
Participants perceive the publication as having significant implications for treatment options in ALK-positive NSCLC patients.
Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainly rash Multiple 1L options in ALK+ NSCLC optimum sequence of TKIs in ALK+ nsclc will be a high priority to study @OncoAlert https://t.co/RU0gf990Ux
Another great option for #alk #lungcancer but why are we still using Crizotinib as a control arm? Ensartinib vs Crizotinib for Patients With ALK-Positive NSCLC with a PFS 26 vs 13 mos (HR 0.51) by @HornLeora Et al. https://t.co/VpEps7iZm2 via @JAMAOnc @ALKLungCancer #lcsm
Interim analysis from eXalt3 @JAMAOnc - phase III randomized trial of ensartinib vs crizotinib as 1L therapy for #ALK NSCLC. Ensartinib is a second generation ALK TKI with CNS efficacy. Clearly superior to crizotinib but what is the impact now? @OncoAlert https://t.co/1bCkcLf1W7
This video explains how ensartinib works for treating ALK-positive non-small cell lung cancer (NSCLC). Recent studies show ensartinib significantly improves progression-free survival compared to crizotinib, highlighting…
In this episode of OncoTrial Insights, we break down the pivotal clinical trial comparing ensartinib and crizotinib for treating ALK-positive metastatic non-small cell lung cancer. Discover key trial findings, side…
Ensartinib Mechanism of Action: New First-Line Option for Advanced ALK-Positive Lung Cancer https://t.co/CXSrpoa6Ka #MedicalEducation #Pharmacology #CancerTreatment #NSCLC #MedicalResearch #Oncology #OncoBites
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive NSCLC https://t.co/mmBPcQ6c33 #lcsm #lungcancer
In a randomized #clinicaltrial, SCI leader Heather Wakelee & colleagues identified ensartinib as a new first-line option for patients with anaplastic lymphoma kinase-positive non-small cell #lungcancer. #nsclc @HwakeleeMD @JAMAOnc https://t.co/wn55rzf1HO
"Ensartinib is a safe and effective therapy for patients with ALK-positive NSCLC" Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive NSCLC | comment: Jean-Yves Douillard MD, PhD https://t.co/YJ4SnJVfQn via @practiceupdate
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive NSCLC https://t.co/CyqB1CURF2 #oncology
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer, A Randomized Clinical Trial: Question Is ensartinib superior to crizotinib for ... #EML4-#ALK #Positive #Research #Ensartinib #Crizotinib Read More: https://t.co/eNHmH6NZqh
RT @JAMAOnc: In a randomized 1L phase 3 (eXalt3) trial in #ALK-positive #NSCLC, PFS was significantly longer with ensartinib vs crizotinib…
In a randomized 1L phase 3 (eXalt3) trial in #ALK-positive #NSCLC, PFS was significantly longer with ensartinib vs crizotinib (NR vs 12.7 months, HR=0.45) by BIRC with a favorable safety profile. CNS ORR was 64% with ensartinib vs 21% with crizotinib https://t.co/MjH8qqaGdx #LCSM
Ensartinib represents a potential new first-line treatment option for patients with ALK-positive NSCLC (lung cancer). https://t.co/DjEmboSVxD https://t.co/sTWi6jgZ60
貝達薬業(中国)のALK陽性NSCLCに対するEnsartinib vs Crizotinib, Phase 3 trial: eXalt3. Primary outcomeのmPFSがEnsartinib 25.8 vs Crizotinib 12.7 months HR0.51 [95% CI, 0.35-0.72]; log-rank P < 0.001, IC-ORRは63.6％(N＝7/11) vs 21.1％(N＝4/19人) https://t.co/qel2Her9Ls
Ensartinib tiene una eficacia superior a crizotinib en enfermedad sistémica e intracraneal en pacientes con cáncer de pulmón de células no pequeñas positivo para ALK https://t.co/xVzWlz7gyJ a través de @JAMAOnc part of @JAMANetwork
RT @atscommunity: Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase−positive #NSCLC: https://t.co/VBGscVhqna
Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase−positive #NSCLC: https://t.co/VBGscVhqna
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer: A Randomized Clinical Trial https://t.co/1ouENjBOIw
A phase III trial in 290 pts with advanced ALK+ NSCLC, frontline ensartinib improved mPFS vs crizotinib (25.8 vs 12.7 months), which seemed to reflect greater CNS activity (intracranial ORR 64% vs 21%; 12-month CNS progression rate 4.2% vs 23.9%): https://t.co/NhiuBNwjnl #lcsm
RT @atscommunity: Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase−positive #NSCLC: https://t.co/VBGscVhqna
Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase−positive #NSCLC: https://t.co/VBGscVhqna
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
RT @Latinamd: Another great option for #alk #lungcancer but why are we still using Crizotinib as a control arm? Ensartinib vs Crizotinib…
RT @Latinamd: Another great option for #alk #lungcancer but why are we still using Crizotinib as a control arm? Ensartinib vs Crizotinib…
Another great option for #alk #lungcancer but why are we still using Crizotinib as a control arm? Ensartinib vs Crizotinib for Patients With ALK-Positive NSCLC with a PFS 26 vs 13 mos (HR 0.51) by @HornLeora Et al. https://t.co/VpEps7iZm2 via @JAMAOnc @ALKLungCancer #lcsm
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
RT @DrJNaidoo: Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainl…
Ph III exalt3 Ensartinib v Crizotinib in ALK-+ NSCLC: - mPFS 25.8 v 12.7mo - CNS RR 63.6% v 21.1% - AEs: 7.7% vs 6.1%, mainly rash Multiple 1L options in ALK+ NSCLC optimum sequence of TKIs in ALK+ nsclc will be a high priority to study @OncoAlert https://t.co/RU0gf990Ux
RT @ALCASEItalia: Dimostrata la superiorità di un nuovo anti-ALK rispetto al vecchio Crizotinib: si chiama ENSARTINIB. https://t.co/40kyXE…
Dimostrata la superiorità di un nuovo anti-ALK rispetto al vecchio Crizotinib: si chiama ENSARTINIB. https://t.co/40kyXE33Ma
RT @StephenVLiu: Interim analysis from eXalt3 @JAMAOnc - phase III randomized trial of ensartinib vs crizotinib as 1L therapy for #ALK NSCL…
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer: A Randomized Clinical Trial | Cancer Biomarkers | JAMA Oncology | JAMA Network https://t.co/I3YITJ9Ec4
RT @StephenVLiu: Interim analysis from eXalt3 @JAMAOnc - phase III randomized trial of ensartinib vs crizotinib as 1L therapy for #ALK NSCL…
RT @StephenVLiu: Interim analysis from eXalt3 @JAMAOnc - phase III randomized trial of ensartinib vs crizotinib as 1L therapy for #ALK NSCL…
RT @StephenVLiu: Interim analysis from eXalt3 @JAMAOnc - phase III randomized trial of ensartinib vs crizotinib as 1L therapy for #ALK NSCL…
eXalt3 study: This open-label phase 3 trial randomized ALK-positive patients with advanced, recurrent, or metastatic ALK-positive to ensartinib or crizotinib. Ensartinib showed superior systemic and intracranial efficacy.. #LCSM https://t.co/XdxRFl9vmx
RT @StephenVLiu: Interim analysis from eXalt3 @JAMAOnc - phase III randomized trial of ensartinib vs crizotinib as 1L therapy for #ALK NSCL…
RT @StephenVLiu: Interim analysis from eXalt3 @JAMAOnc - phase III randomized trial of ensartinib vs crizotinib as 1L therapy for #ALK NSCL…
Interim analysis from eXalt3 @JAMAOnc - phase III randomized trial of ensartinib vs crizotinib as 1L therapy for #ALK NSCLC. Ensartinib is a second generation ALK TKI with CNS efficacy. Clearly superior to crizotinib but what is the impact now? @OncoAlert https://t.co/1bCkcLf1W7
RT @DrMeredithGT:
RT @Dr_Ivanoncologo:
RT @DrMeredithGT:
RT @DrMeredithGT:
RT @Dr_Ivanoncologo:
RT @Dr_Ivanoncologo:
Ensartinib vs Crizotinib for Patients With ALK-Positive NSCLC https://t.co/pb5ODkmrxL @JAMAOnc part of @JAMANetworkより
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer: A Randomized Clinical Trial | Cancer Biomarkers | JAMA Oncology | JAMA Network https://t.co/U5N5SLPAdM
RT @Dr_Ivanoncologo:
Ensartinib demonstrated better efficacy than crizotinib against systemic and intracranial disease in patients with ALK-positive #NSCLC, study finds https://t.co/SIpsD0FCOG via @JAMAOnc part of @JAMANetwork
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial #lymphoma #lymsm https://t.co/G0piC2UZKY
Ensartinib shows superior efficacy to crizotinib in both systemic and intracranial disease in ALK +ve NSCLC https://t.co/bkTXP6eLnb https://t.co/e9uffuk3SG
New article: Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial https://t.co/pMOGCoqpDI #lungcancer #oncology https://t.co/k1pckR67zL
Spoilt for choice with ALK inhibitors. If only it was a common mutation! #lcsm Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer: A Randomized Clinical Trial | Cancer Biomarkers | JAMA Oncology https://t.co/oKuyvs8HSp
RT @DrLesterColl:
RT @DrLesterColl:
RT @DrLesterColl:
RT @DrLesterColl:
RT @DrLesterColl:
RT @DrLesterColl:
RT @DrLesterColl:
RT @DrLesterColl:
RT @VivekSubbiah: Ensartinib vs Crizotinib for Patients With ALK-Positive NSCLC https://t.co/rlHpiG98iJ via @JAMAOnc part of @JAMANetwork
Ensartinib vs Crizotinib for Patients With ALK-Positive NSCLC https://t.co/rlHpiG98iJ via @JAMAOnc part of @JAMANetwork
In a randomized 1L phase 3 (eXalt3) trial in #ALK-positive #NSCLC, PFS was significantly longer with ensartinib vs crizotinib (NR vs 12.7 months, HR=0.45) by BIRC with a favorable safety profile. CNS ORR was 64% with ensartinib vs 21% with crizotinib #LCSM https://t.co/weA88fbxXk
RT @DrLesterColl:
RT @DrLesterColl:
RT @DrLesterColl: